151751-Najiba-Chargi

333 Systemic therapy: skeletal muscle mass and functional outcomes Appendix 5. Speech outcomes at t0, t1 and t2 stratified by treatment modality. RT CRT (cetuximab) CRT (cisplatin) t 0 n = 42 t 1 n = 39 t 2 n = 28 t 0 n = 17 t 1 n = 17 t 2 n = 11 t 0 n = 49 t 1 n = 43 t 2 n = 32 Observer-rated outcomes Vowel Space Area (%) Median (range) 92 (61-128) 86 (56-107) 83 (53-112) 86 (68-129) 74 (59-97) 69 (53-96) 81 (51-114) 76 (49-102) 76 (51-97) Vowel Space Area < 80% No 25 (76) 20 (69) 13 (59) 10 (63) 6 (38) 2 (22) 24 (53) 11 (36) 9 (35) Yes 8 (24) 9 (31) 9 (41) 6 (38) 10 (63) 7 (78) 21 (47) 20 (65) 17 (65) Unknown 9 10 6 1 1 2 4 12 6 Patient-rated outcomes SHI Median (range) Speech domain (0–56) 1 (0-18) 2 (0-21) 0 (0-14) 0 (0-25) 2 (0-27) 0 (0-6) 0 (0-42) 2 (0-32) 1 (0-31) Psychosocial domain (0–56) 0 (0-5) 0 (0-10) 0 (0-7) 0 (0-32) 0 (0-34) 0 (0-1) 0 (0-39) 0 (0-19) 0 (0-15) Total score (0–120) 1 (0-23) 2 (0-36) 0 (0-23) 0 (0-57) 2 (0-61) 0 (0-6) 0 (0-83) 3 (0-52) 1 (0-40) SHI ≥ 6 No 23 (82) 13 (65) 16 (94) 12 (86) 10 (77) 6 (86) 30 (83) 16 (62) 14 (82) Yes 5 (18) 7 (35) 1 (6) 2 (14) 3 (23) 1 (14) 6 (17) 10 (39) 3 (18) Unknown 14 19 11 3 4 4 13 17 15 Secondary outcomes Articulation rate (syllables/s) Median (range) 2.2 (0.9-7.7) 2.8 (1.4-4.2) 2.9 (0.1-5.0) 2.7 (1.0-4.3) 2.6 (0.6-4.6) 2.7 (1.6-5.1) 2.2 (0.2-5.8) 2.6 (0.6-6.1) 2.4 (0.6-6.1) AVQI Median (range) 4.7 (3.7-5.3) 4.5 (3.4-5.5) 4.7 (4.1-5.3) 4.4 (3.7-5.1) 4.4 (3.6-5.1) 4.5 (4.1-5.2) 4.5 (3.3-5.2) 4.5 (3.5-5.3) 4.5 (3.6-5.5) NB: Not all percentages sum up exactly to 100% due to rounding. Abbreviations: AVQI = acoustic voice quality index, FOIS = functional oral intake scale, SHI = speech handicap index, t0 = pretreatment, t1 = six months after treatment, t2 = twelve months after treatment 17